Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069243 | 0.86 | SLC6A4 (0.52) | PDE2ASLC6A4SLC6A2HTR2AHTR2C | |
| SCHEMBL17069303 | 0.84 | ATM (0.48) | PDE2A | |
| SCHEMBL23841644 | 0.81 | DAO (0.44) | PDE2ADAOSLC6A4SLC6A2MC4R | |
| SCHEMBL12304037 | 0.80 | IDO1 (0.53) | PDE2ADAOSLC6A4SLC6A2MC4R | |
| SCHEMBL29453102 | 0.80 | IDO1 (0.53) | PDE2ADAOSLC6A4SLC6A2MC4R | |
| SCHEMBL12844885 | 0.80 | PDE3B (0.45) | PDE2ADAOSLC6A4SLC6A2HTR2A | |
| SCHEMBL3208015 | 0.79 | PDE2A (0.49) | PDE2ADAOSLC6A4SLC6A2HTR2A | |
| SCHEMBL2669965 | 0.79 | DAO (0.51) | PDE2ADAOSLC6A4HTR2AKCNH2 | |
| SCHEMBL21102201 | 0.77 | HTR2A (0.40) | PDE2ASLC6A4SLC6A2HTR2AHTR2C | |
| SCHEMBL17069232 | 0.77 | PDE2A (0.40) | PDE2ASLC6A4SLC6A2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210386065-A1 | MIXTURE OF MECTINS AND PYRETHROIDS AND USES THEREOF | VALENT BIOSCIENCES LLC | 2021-12-16 | — | — | US | disclosed |
| EP-2913325-B1 | SUBSTITUTED PYRIMIDINE COMPOUND AND USES THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210015100-A1 | SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015100-A1 | SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | GART, BROX, APRT | PDE2A 1599/4885DAO 105/4885SLC6A4 4202/4885 |
| US-20210386065-A1 | MIXTURE OF MECTINS AND PYRETHROIDS AND USES THEREOF | ACHE, DDT, PTMS | PDE2A 625/4885DAO 2520/4885SLC6A4 2725/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | PDE2A 573/4885DAO 3011/4885SLC6A4 1222/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | PDE2A 1204/4885DAO 3087/4885SLC6A4 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.